Asymchem Laboratories Breaks Ground For Jilin Production Base
This article was originally published in PharmAsia News
Asymchem Laboratories, a leading pharmaceutical CRO in China, recently started constructing its new 220,000-square-meter production facility in Jilin Dunhua Economic Development Zone. With total investment of 240 million yuan, Asymchem Laboratories (Jilin) will house FDA cGMP-compliant clean manufacturing space, supply stores and an advanced international-standard EHS control center that produces high-level active pharmaceutical ingredients, pharmaceutical intermediates and relevant basic raw materials. The project's first phase is expected to be fully operational in early 2009 with an annual output of over 30 tons to achieve production value of 1.5 billion yuan within three years. (Click here for more - Chinese Language)
You may also be interested in...
Guardant’s CEO anticipates accelerated adoption and reimbursement of its FDA-approved liquid biopsy assay and more biopharma partnerships.
Public Company Edition: The German mRNA-focused company could raise up to $245m based on its proposed price range, but investor interest could drive the offering’s total higher. Also, Perceptive launches another SPAC, Regeneron sells $2bn in debt and Biohaven secures up to $950m.
Agency commissioner appeals to AMA audience to communicate message that FDA review decisions are based on good science.